Japan is facing problems associated with "heart failure (HF) pandemics" and bed shortages in core hospitals that can accommodate patients with acute HF. The prognosis is currently unknown for acute HF patients who were transferred from core hospitals to collaborating hospitals during the very early treatment phase and whose treatment strategies are in place.
A cute heart failure (HF) is one of the leading causes of hospitalization, and it is associated with high morbidity and mortality, high readmission rates, and heavy burdens on health insurance systems. 1) The United States has approximately 6.5 million HF patients, and the prevalence of HF has been predicted to increase by 46% from 2012 to 2030; hence, over 8 million people will have HF. 2) In Japan, the number of patients with HF is predicted to increase to 1.3 million by 2030. 3) These situations are referred to as "HF pandemics." Moreover, patients with HF are admitted to hospitals for a median duration of approximately 21 days in Japan, which is longer than that in other countries. 1) One major reason underlying the longer hospitalization duration in Japan is the notable aging of the population. In 2015, 9.5 million (7.7%) people were over 80 years of age, and 1.8 million (1.4%) people were over 90 years of age. Estimations indicate that by 2050, the proportions of people in these age groups will have increased to 16.2% and 5.0%, respectively. 4) Compared with younger patients, elderly patients tend to lead more solitary lives and have lower activities of daily living (ADLs). Consequently, there will be a shortage of beds in core hospitals that can accommodate patients with acute HF.
A potentially useful approach toward tackling the HF pandemic is to encourage regional cooperation between core hospitals and collaborating hospitals. The Japanese Red Cross Musashino Hospital is a general hospital that has 611 beds and over 200 doctors. This hospital plays a central role because it accepts as many patients as possible and focuses on acute-phase treatment. We usually transfer patients who are hospitalized with acute HF to collaborating hospitals that have at least one full-time cardiologist during the very early treatment phase. However, collaborating hospitals cannot manage patients with severe HF who require ventilation or emergent patients who present at night because of labor shortages. Nevertheless, the staff at these hospitals can determine medication doses by titration and arrange social care and rehabilitation for stabilized patients. The aim of this study was to assess whether the prognosis of patients who were hospitalized for acute HF and were transferred to collaborating hospi-EARLY PATIENT TRANSFER AND ACUTE HF PROGNOSIS tals was comparable with that of patients who were not transferred.
Methods

Study population:
We registered 210 consecutive patients who were !20 years old and had been diagnosed and hospitalized with acute HF between January 1, 2015, and December 31, 2015. Acute HF was diagnosed using the Framingham criteria. 5) Patients were excluded if they had undergone heart transplantation, are undergoing chronic peritoneal dialysis or hemodialysis, had acute myocarditis, or had acute coronary syndrome requiring emergent/urgent revascularization. Patients who did not have data that described their brain natriuretic peptide (BNP) levels and those with BNP levels < 100 pg/mL at baseline were also excluded. Patients who were lost to follow-up at one year after discharge from the core hospital were excluded (n = 2). We ultimately enrolled 166 eligible patients with a mean age of 78.8 ± 11.0 years to participate in this study ( Figure 1 ). Among these patients, 49.4% were men. To validate the influence of the transferring hospital, we compared the clinical outcomes starting from the time of admission to the core hospital. Furthermore, to avoid immortal time bias, we performed landmark analyses to compare the clinical outcomes from 0 to 30 days and from 31 days to 1 year after the admission to the core hospital ( Figure 1) .
The patients' medical teams, which comprise the attending physicians, cardiologists, nurses, and other medical staff, decides whether a patient should be transferred to a collaborating hospital on the first day of hospitalization. The criteria used to transfer patients were as follows: (1) precision inspections for investigating the etiology of HF, such as coronary angiography or cardiac magnetic resonance imaging, were unnecessary owing to previous investigations; (2) poor socioeconomic status, particularly in relation to patients living alone and without support from family members; (3) poor ADL status and the need for rehabilitation; and (4) age of more than 80 years old. Criteria 2 to 4 is related to the estimated duration of hospitalization. We selected the hospital according to accessibility from the patients' residence and the speed of reply indicating acceptance. We usually transfer patients after finishing acute or intensive treatment, which includes withdrawal from ventilation, intravenous diuretics, or catecholamine. Our medical team simultaneously assessed the need for nutritional intervention, rehabilitation, and introduction of care insurance to support the socioeconomic status of patients and then conveyed this information to the staff at the collaborating hospitals. Consequently, 53 patients were transferred to the collaborating hospitals (transfer group: n = 53, mean age, 84.0 ± 9.0 years), and 113 patients were not transferred (nontransfer group: n = 113, mean age, 76.4 ± 11.1 years).
This study conformed to the ethical principles of the Declaration of Helsinki and the Japanese Ethical Guidelines for Medical and Health Research Involving Human Subjects. The requirement for informed consent was waived because all data were cataloged anonymously. The institutional review board of the Japanese Red Cross Musashino Hospital approved the study's protocol. The in-formation disclosure document associated with this study is available on the hospital's website. All patients were notified about their participation in the study and were informed that they can withdraw their participation at any time. Data collection: We reviewed the patients' medical records and obtained data describing their ages, sexes, heights, weights, socioeconomic status, initial vital signs (systolic blood pressure (BP), diastolic BP, and heart rate), laboratory test results on admission, and presence of concomitant diseases (e.g., hypertension, which was defined as a BP !140/90 mmHg; history of hypertension; history of taking antihypertensive medications; diabetes mellitus (DM); coronary artery disease; and chronic obstructive pulmonary disease (COPD)). The left ventricular ejection fraction (EF) was assessed by echocardiography in the emergency department, and the EFs of the patients were categorized into three groups: < 35%, 35%-50%, and > 50%. The New York Heart Association (NYHA) classifications and composite congestion scores (CCSs) 6) of the patients were evaluated when the patients were discharged from the core hospital.
After discharge, most of the patients were followed up in outpatient clinics at the collaborating hospitals or were visited by practitioners who specialize in cardiology. The causes and timings of the cardiovascular (CV) events that occurred after the patients' discharge from the core hospital were obtained from hospital records or through telephone interviews with the families of the deceased. We classified the causes of death and HF readmission by using the ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials. 7) Patients who were alive on March 1, 2017, were censored for overall survival analysis. Statistical analyses: Data that describe the normally distributed variables are expressed as means and standard deviations, and data describing the nonnormally distributed variables are expressed as medians with interquartile ranges (IQRs). Categorical data are expressed as numbers and percentages. We used Welch's t-test or the Wilcoxon rank-sum test to compare the continuous variables and used the chi-square test or Fisher's exact test to compare the categorical variables. The Kaplan-Meier method was used to estimate survival, and the differences between the survival curves were assessed using the Mantel-Cox logrank test. Landmark analyses were conducted from 0 to 30 days and from 31 days to 1 year after admission to the core hospital. The Meta-analysis Global Group in Chronic Heart Failure (MAGGIC) risk score was calculated for each patient as described previously.
8) The MAGGIC risk score is based on 13 independent predictors of long-term mortality, including age, sex, systolic BP, EF, body mass index, creatinine level, NYHA class, DM, COPD, current smoker, HF diagnosis in the past 18 months, and not prescribed beta-blockers, angiotensin-converting enzyme inhibitors, or angiotensin-receptor blockers. We used the MAGGIC risk score as an adjustment variable in a multivariable prognostic model. A Cox proportional hazard model was used to evaluate the association between a hospital transfer and the one-year prognosis. Statistical analyses were performed using the R statistical package version 3.1.0 (The R Foundation for Statistical Computing Vienna, Austria; http://www.r-project.org/). A two-sided P value < 0.05 was considered statistically significant.
Results
Patients' characteristics:
The transfer and nontransfer group comprised 53 and 113 patients, respectively (Table  I ). The patients in the transfer group were older and shorter, had lower body weights, were more likely to be solitary, had lower albumin levels, and had higher initial BNP levels than the patients in the nontransfer group. The groups were similar with regard to the presence of concomitant factors (e.g., history of HF, hypertension, DM, coronary artery disease, and COPD) and the use of ventilators. The patients in the two groups also had similar blood urea nitrogen (BUN) and sodium levels. Clinical outcomes: Upon discharge from the core hospital, the median duration of the hospital stay was significantly shorter in the transfer group than in the nontransfer group (6 [IQR, 4-14] days versus 10 [IQR, 7-15] days, P = 0.001) ( Table II) . The median duration of the total hospital stay, which comprised the core hospital stay and the collaborating hospital stay, in the transfer group was 16 days. Although the furosemide dose during the initial 48 hours was significantly higher in the transfer group than in the nontransfer group (100 [IQR, 80-125] mg versus 80 [IQR, 60-120] mg, P = 0.026), the groups were similar in relation to the total volume of urine excreted over 48 hours, the maximum creatinine level, and the maximum BUN level. More than half of the patients had CCSs of 0-1 and were categorized as NYHA classes 1 and 2 when they were transferred. The NYHA class and the frequency of a CCS score > 2 were significantly higher in the transfer group. The MAGGIC risk score was higher in the transfer group (31. At 1-year follow-up, 35 patients (21.1%) had died, and 54 patients (32.5%) had experienced composite events of death and/or HF readmission (Table II) . No significant differences were observed with respect to the cause of death between the groups, except for non-CV deaths. The Kaplan-Meier analyses for comparisons of the transfer group and the nontransfer group indicated similar allcause mortality rates (24.5% versus 19.5%, log-rank P = 0.27) and composite death and HF readmission rates (35.8% versus 31.0%, log-rank P = 0.32) (Figure 2A and B). The landmark Kaplan-Meier analyses that compared the transfer group and nontransfer group showed similar all-cause mortality rates from 0 to 30 days (3.8% versus 3.5%, log-rank P = 0.89) ( Figure 3A) and from 31 days to 1 year (21.6% versus 16.5%, log-rank P = 0.39) (Figure 3B) . Patients in the transfer group who had CCSs of 0-1 had a significantly lower composite death and HF readmission rate than those who had CCSs !2 (23.5% versus 57.9%, log-rank P = 0.005) (Figure 4) . Table III shows the results from the univariate and multivariate Cox proportional hazard model analyses. Transfers to the collaborating hospitals were not associated with higher mortality rates or higher composite mortality and HF readmission rates even after adjusting for EARLY PATIENT TRANSFER AND ACUTE HF PROGNOSIS The data are expressed as numbers (%), means and standard deviations, or medians and interquartile ranges. LVEF indicates left ventricular ejection fraction; NYHA, New York Heart Association; NPPV, noninvasive positive pressure ventilation; ICU, intensive care unit; COPD, chronic obstructive pulmonary disease; ED, emergency department; WBC, white blood cell; BUN, blood urea nitrogen; CRP, C-reactive protein; and BNP, brain natriuretic peptide.
the MAGGIC risk score.
Discussion
In this study, we compared the clinical outcomes of acute HF patients who were treated initially in core hospitals but were then transferred to collaborating hospitals that had at least one cardiologist at the very early treatment stage (i.e., after six days in the core hospital) with the clinical outcomes of acute HF patients who were not transferred. The main finding from this study was that compared with patients who were not transferred, the transferred patients had similar mortality rates and composite mortality and HF readmission rates one year after admission to the core hospital when the treatment strategies were correctly implemented by cardiologists. Furthermore, the implementation of strict decongestion strategies during the initial hospitalization in the core hospital may be associated with the favorable outcomes that followed the transfer of the patients to the collaborating hospitals. The data are expressed as numbers (%), means and standard deviations, or medians and interquartile ranges. BUN indicates blood urea nitrogen; NYHA, New York Heart Association; MAGGIC, Meta-analysis Global Group in Chronic Heart Failure; ACE-I, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BB, beta blocker; ACS, acute coronary syndrome; HF, heart failure; CV, cardiovascular; and SCD, sudden cardiac death.
The findings from a Japanese study of a large patient cohort, namely, the acute decompensated heart failure syndromes (ATTEND) registry, showed that the median duration of hospitalization was approximately 21 days and that EARLY PATIENT TRANSFER AND ACUTE HF PROGNOSIS the 1-year mortality rate and composite mortality and HF readmission rates were 21.8% and 37.9%, respectively.
1)
On the other hand, the findings from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) trial, which was performed in westernized countries, showed that the median duration of hospitalization was approximately seven days and that the one-year mortality rate and composite mortality and HF readmission rates were 26.4% and 44.3%, respectively.
6)
The outcomes of these studies were surprisingly similar despite the shorter hospital stay in the EVEREST trial; this finding may be explained by features that appear to be specific to Japan, for example, older and frailer patients being unable to easily return to their own homes and the national health insurance system covering long hospital stays. In the current study, the median durations of hospitalization in the core hospital were 6 days for the transfer group and 10 days for the nontransfer group, which are shorter than the duration of hospitalization in the Japanese study that evaluated the data from the large ATTEND registry and are similar to the duration of hospitalization in the EVEREST trial. One key reason for this difference is that there are 600 beds per 100,000 people or 14% fewer general hospital beds in our medical zone than the average number of general hospital beds in Japan (696 beds per 100,000 people). 9) Therefore, the reduction of hospitalization duration is important, particularly in core hospitals. The findings from our study demonstrate that regional cooperation helps shorten hospital stays in core hospitals without negatively affecting patient outcomes, particularly for elderly and solitary patients. The proportion of patients categorized as NYHA classes 3 and 4 at the time of discharge from the core hospital was higher in the transferred group than in the nontransferred group, and this finding may be associated with the length of hospital stay in the core hospital, which was shorter in the transferred group than in the nontransferred group (6 days versus 10 days, respectively). Consequently, the decongestion might not have been completed in some patients in the transferred group at the time of transfer. In 2015, the medical insurance system reimbursed the hospital transfer cost only within 7 days from the initial admission; therefore, most collaborating hospitals preferred to accept patients within 7 days from the initial admission, and some patients were transferred even if decongestion was not yet complete. However, we did not transfer patients who required ventilation. Furthermore, we precisely communicated the treatment strategy, including the diuretic dose and titration of guideline-directed medical treatment, to the full-time cardiologists in the collaborating hospitals. This continuation of medical therapy in the collaborating hospitals may explain the similar prognoses in the transfer and nontransfer groups in this study. Staff in the collaborating hospitals arranges the patients' social care and organizes the rehabilitation of patients with low ADL. This type of supervision may improve the outcomes of transferred patients. 10) Moreover, the total hospital stay in the transfer group was 16 days, which is shorter than that in the study that evaluated the data within the ATTEND registry even though the patients in the transfer group of the current study were older than those in the ATTEND registry (84.0 years versus 73.0 years, respectively).
1) The findings from a previous study 11) showed that a longer period of hospitalization itself is a risk for impaired ADL; therefore, shortening the duration of hospital stay may be effective in preventing the risk of social frailty, particularly among elderly patients.
The findings from the EVEREST study also showed that implementing a strict decongestion regimen before discharge reduced the frequency of adverse events. 6) In this study, approximately 60% of the patients in the transfer group and 80% of patients in the nontransfer group had low CCSs of 0-1 when they were discharged from the core hospital. Patients who were transferred and had low CCSs had significantly lower composite death and HF readmission rates at one year than patients who were transferred and had high CCSs. This result indicated the importance of an early and strictly implemented decongestion regimen for reducing the number of CV events after transfer to the collaborating hospitals. More furosemide was administered to patients in the transfer group, thus indicating that physicians struggled to achieve decongestion before transfer. However, the maximum creatinine and the BUN levels in the transfer group did not differ significantly compared with those in the nontransfer group.
Study limitations:
The results from this study should be evaluated in the context of its many limitations. First, the study's small sample size may be a limitation. Although we carefully selected 166 patients for enrollment, this cohort was smaller than those evaluated in previous multicenter studies, and the small sample size may have affected our results. However, this type of survey may be difficult to conduct as a randomized trial or as a multicenter study because of the different transfer policies and collaborating hospitals' characteristics among hospitals and regions. To our knowledge, this is the first report that describes the prognostic impact of regional cooperation on the outcomes of hospitalized HF patients in Japan. Second, this study was a retrospective, single-center, observational study, and the confounding factors may have affected the results. Although we attempted to adjust for the confounders as much as possible by using a risk score that comprises 13 important predictors and is widely used in the prediction of long-term prognoses, an unadjusted confounding factor may have persisted. Therefore, our results should be interpreted very cautiously. Residual confounders may have remained because the study's regional specificity may have affected the results. Furthermore, patient transfers were decided by group discussions, which may have influenced the results. Data that describe the ADLs and frailty-related scores were absent, and these could be residual confounding factors. Third, we did not have detailed descriptions of the patients' treatment in the collaborating hospitals. However, as mentioned above, we precisely communicated the treatment strategy to the fulltime cardiologists in the collaborating hospitals. Fourth, mortality and HF readmission at one year were the only outcomes evaluated in this study, and data describing other important factors (e.g., renal function, medications used during the study period, and ADLs) were lacking.
Conclusions
Our analysis demonstrated that both the one-year mortality rate and the composite mortality and HF readmission rates for acute HF patients who were transferred from core hospitals to collaborating hospitals at a very early treatment stage were not inferior to those of patients who were not transferred when the treatment strategies were correctly implemented by cardiologists even after adjusting for the MAGGIC risk score. The implementation of early and strict decongestion regimens during initial hospitalization in the core hospital may be associated with favorable outcomes after patient transfer to collaborating hospitals.
